Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Judith Meza-Junco & Michael B Sawyer. (2012) Metastatic gastric cancer – focus on targeted therapies. Biologics: Targets and Therapy 6, pages 137-146.
Read now
Read now
Articles from other publishers (18)
Korri E El-Khobar, Enoch Tay, Eve Diefenbach, Brian S Gloss, Jacob George & Mark W Douglas. (2023) Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer. Life Science Alliance 6:11, pages e202201630.
Crossref
Crossref
Ruxin Shen, Zhaoshui Li & Xiaoting Wu. (2023) The mitotic spindle-related seven-gene predicts the prognosis and immune microenvironment of lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology 149:12, pages 10131-10141.
Crossref
Crossref
Man-Li Luo, Jingjing Li, Liping Shen, Junjun Chu, Qiannan Guo, Guorun Liang, Wei Wu, Jianing Chen, Rufu Chen & Erwei Song. (2020) The Role of APAL/ST8SIA6-AS1 lncRNA in PLK1 Activation and Mitotic Catastrophe of Tumor Cells. JNCI: Journal of the National Cancer Institute 112:4, pages 356-368.
Crossref
Crossref
Liang Yan, Yizonheng Zhang, Kai Li, Mengze Wang, Jiaping Li, Zhilin Qi, Juan Wu, Zhen Wang, Liefeng Ling, Haijun Liu, Yaohua Wu, Xinyu Lu, Lei Xu, Yiping Zhu & Yao Zhang. (2020) miR-593-5p inhibit cell proliferation by targeting PLK1 in non small cell lung cancer cells. Pathology - Research and Practice 216:2, pages 152786.
Crossref
Crossref
Jolien Van den Bossche, Christophe Deben, Ines De Pauw, Hilde Lambrechts, Christophe Hermans, Vanessa Deschoolmeester, Julie Jacobs, Pol Specenier, Patrick Pauwels, Jan Baptist Vermorken, Marc Peeters, Filip Lardon & An Wouters. (2019)
In vitro
study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
. Molecular Oncology 13:5, pages 1196-1213.
Crossref
Crossref
Kazuhisa Ishimoto, Keiichiro Nakaoka, Osamu Yabe, Atsuko Nishiguchi & Tomomi Ikemoto. (2018) A practical chromatography-free synthesis of a 5,6-dihydroimidazolo[1,5-f]pteridine derivative as a polo-like kinase-1 inhibitor. Tetrahedron 74:39, pages 5779-5790.
Crossref
Crossref
J. Van den Bossche, F. Lardon, V. Deschoolmeester, I. De Pauw, J.B. Vermorken, P. Specenier, P. Pauwels, M. Peeters & A. Wouters. (2016) Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor. Medicinal Research Reviews 36:4, pages 749-786.
Crossref
Crossref
Dorothea Rudolph, Maria Antonietta Impagnatiello, Claudia Blaukopf, Christoph Sommer, Daniel W. Gerlich, Mareike Roth, Ulrike Tontsch-Grunt, Andreas Wernitznig, Fabio Savarese, Marco H. Hofmann, Christoph Albrecht, Lena Geiselmann, Markus Reschke, Pilar Garin-Chesa, Johannes Zuber, Jürgen Moll, Günther R. Adolf & Norbert Kraut. (2015) Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia. Journal of Pharmacology and Experimental Therapeutics 352:3, pages 579-589.
Crossref
Crossref
Joseph E. Klebba, Daniel W. Buster, Tiffany A. McLamarrah, Nasser M. Rusan & Gregory C. Rogers. (2015) Autoinhibition and relief mechanism for Polo-like kinase 4. Proceedings of the National Academy of Sciences 112:7.
Crossref
Crossref
Melanie Janning & Walter Fiedler. (2014) Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. Future Oncology 10:7, pages 1157-1165.
Crossref
Crossref
Christin Lund-Andersen, Sebastian Patzke, Viola Nähse-Kumpf & Randi G. Syljuåsen. (2014) PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule. Radiotherapy and Oncology 110:2, pages 355-361.
Crossref
Crossref
Robert H. Mach, Chenbo Zeng & William G. Hawkins. (2013)
The σ
2
Receptor: A Novel Protein for the Imaging and Treatment of Cancer
. Journal of Medicinal Chemistry 56:18, pages 7137-7160.
Crossref
Crossref
Ahmet Tunceroglu & Salma K Jabbour. (2013) Gastric cancer: past accomplishments, present approaches and future aspirations. Clinical Practice 10:1, pages 47-77.
Crossref
Crossref
Christophe Wiart. 2013. Lead Compounds from Medicinal Plants for the Treatment of Cancer. Lead Compounds from Medicinal Plants for the Treatment of Cancer
1
95
.
David A. Canton, C. Dirk Keene, Katie Swinney, Lorene K. Langeberg, Vivian Nguyen, Laurence Pelletier, Tony Pawson, Linda Wordeman, Nephi Stella & John D. Scott. (2012) Gravin Is a Transitory Effector of Polo-like Kinase 1 during Cell Division. Molecular Cell 48:4, pages 547-559.
Crossref
Crossref
Barbara Valsasina, Italo Beria, Cristina Alli, Rachele Alzani, Nilla Avanzi, Dario Ballinari, Paolo Cappella, Michele Caruso, Alessia Casolaro, Antonella Ciavolella, Ulisse Cucchi, Anna De Ponti, Eduard Felder, Francesco Fiorentini, Arturo Galvani, Laura M. Gianellini, Maria L. Giorgini, Antonella Isacchi, Jaqueline Lansen, Enrico Pesenti, Simona Rizzi, Maurizio Rocchetti, Francesco Sola & Jürgen Moll. (2012) NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies. Molecular Cancer Therapeutics 11:4, pages 1006-1016.
Crossref
Crossref
Matthew O. Duffey, Tricia J. Vos, Ruth Adams, Jennifer Alley, Justin Anthony, Cynthia Barrett, Indu Bharathan, Douglas Bowman, Nancy J. Bump, Ryan Chau, Courtney Cullis, Denise L. Driscoll, Amy Elder, Nancy Forsyth, Jonathan Frazer, Jianping Guo, Luyi Guo, Marc L. Hyer, David Janowick, Bheemashankar Kulkarni, Su-Jen Lai, Kerri Lasky, Gang Li, Jing Li, Debra Liao, Jeremy Little, Bo Peng, Mark G. Qian, Dominic J. Reynolds, Mansoureh Rezaei, Margaret Porter Scott, Todd B. Sells, Vaishali Shinde, Qiuju Judy Shi, Michael D. Sintchak, Francois Soucy, Kevin T. Sprott, Stephen G. Stroud, Michelle Nestor, Irache Visiers, Gabriel Weatherhead, Yingchun Ye & Natalie D’Amore. (2011) Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905). Journal of Medicinal Chemistry 55:1, pages 197-208.
Crossref
Crossref
Shaoqing Chen, David Bartkovitz, Jianping Cai, Yi Chen, Zhi Chen, Xin-Jie Chu, Kang Le, Nam T. Le, Kin-Chun Luk, Steve Mischke, Goli Naderi-Oboodi, John F. Boylan, Tom Nevins, Weiguo Qing, Yingsi Chen & Peter M. Wovkulich. (2012) Identification of novel, potent and selective inhibitors of Polo-like kinase 1. Bioorganic & Medicinal Chemistry Letters 22:2, pages 1247-1250.
Crossref
Crossref